Filtered By:
Specialty: Drugs & Pharmacology
Drug: Coumadin

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 300 results found since Jan 2013.

Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry
ConclusionsThe quality of warfarin treatment was strongly associated with the risk of stroke and the prognosis of AF patients. Patient outcomes continued to improve with increasing TTR values up to a TTR ≥80%; therefore, the target for the TTR should exceed 80% instead of the traditional range of at least 60–70%. Copyright © 2017 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - February 28, 2017 Category: Drugs & Pharmacology Authors: Mika Lehto, Jussi Niiranen, Pasi Korhonen, Juha Meht älä, Houssem Khanfir, Fabian Hoti, Riitta Lassila, Pekka Raatikainen Tags: Original Report Source Type: research

Edoxaban in Atrial Fibrillation and Venous Thromboembolism —Ten Key Questions and Answers: A Practical Guide
AbstractEdoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.
Source: Advances in Therapy - February 12, 2017 Category: Drugs & Pharmacology Source Type: research

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation
AbstractDabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk factors. Dabigatran etexilate is a prodrug of dabigatran, a direct inhibitor of thrombin. In patients with NVAF in the phase  III RE-LY trial, dabigatran etexilate dosages of 110 and 150 mg twice daily were noninferior to warfarin with regard to the risk of stroke or systemic embolism (primary efficacy endpoint). The higher dosage was associated with a significantly lower risk of stroke or systemic embolism than warfari n, with no si...
Source: Drugs - February 8, 2017 Category: Drugs & Pharmacology Source Type: research

Edoxaban: A direct oral anticoagulant.
CONCLUSION: A review of the literature showed that edoxaban, the most recently approved DOAC, is noninferior to warfarin for management of VTE (after parenteral anticoagulant therapy) and for stroke risk reduction in many patients with nonvalvular AF. PMID: 28122753 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - January 28, 2017 Category: Drugs & Pharmacology Authors: Poulakos M, Walker JN, Baig U, David T Tags: Am J Health Syst Pharm Source Type: research

Optimizing the use of oral anticoagulant therapy for atrial fibrilation in primary care: a pharmacist-led intervention
Conclusion A pharmacist-led intervention re-aligned oral anticoagulant therapy to the latest evidence based guidelines for stroke prophylaxis, whilst simultaneously correcting the over-utilisation of antiplatelet therapy.
Source: International Journal of Clinical Pharmacy - January 2, 2017 Category: Drugs & Pharmacology Source Type: research

Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions
ConclusionsAs well as pre‐marketing authorization clinical trial studies, we found a reduced risk of intracranial haemorrhage, but an increased risk of gastrointestinal haemorrhage in patients treated with DOACs compared to warfarin. We provide new data and we highlight several differences between the three novel oral anticoagulants, in the rate and type of ADRs occurred.
Source: British Journal of Clinical Pharmacology - December 31, 2016 Category: Drugs & Pharmacology Authors: Luca Monaco, Chiara Biagi, Valentino Conti, Mauro Melis, Monia Donati, Mauro Venegoni, Alberto Vaccheri, Domenico Motola Tags: DRUG SAFETY Source Type: research

Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment
ConclusionApixaban appears to be a reasonable alternative to warfarin in patients with severe renal impairment.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 31, 2016 Category: Drugs & Pharmacology Authors: Brooke E. Stanton, Naomi S. Barasch, Katie B. Tellor Tags: Original Research Article Source Type: research

The cost savings of newer oral anticoagulants in atrial fibrillation-related stroke prevention 
.
CONCLUSION: AF stroke patients incurred higher total direct costs compared to non-AF cases. However, more cost savings were evident with NOACs, due to more strokes being prevented through the use of NOACs compared to warfarin.
. PMID: 28025962 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Pharmacology and Therapeutics - December 28, 2016 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

Oral antiplatelet and anticoagulant agents in the prevention and management of ischemic stroke.
Abstract Despite numerous advances over the last 50 years, stroke continues to be a leading cause of death and disability worldwide. The treatment and prevention of stroke has undergone extensive study, and significant advances in medical management have occurred within the past decade principally with the development of new classes of orally active anticoagulant drugs. Here we review these recent breakthroughs and the varying roles of anticoagulants and antiplatelet agents in the prevention and management of different ischemic stroke subtypes, as well as describe the benefits and ongoing challenges to incorporati...
Source: Current Pharmaceutical Design - December 20, 2016 Category: Drugs & Pharmacology Authors: Shrestha S, Coy S, Bekelis K Tags: Curr Pharm Des Source Type: research

Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
ConclusionsApixaban was more cost effective than warfarin, dabigatran, and rivaroxaban for stroke prevention in patients with AF. Among the anticoagulant therapies, the WTP threshold of apixaban was about US$50,000 per QALY gained. These cost-effectiveness estimations provide useful information to aid clinical decision making in stroke prevention for AF patients.
Source: Clinical Drug Investigation - December 16, 2016 Category: Drugs & Pharmacology Source Type: research

Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation.
Authors: Marín F, Anguita Sánchez MP, Sanmartín Fernández M Abstract INTRODUCTION: Patients with atrial fibrillation have an increased risk for stroke, systemic embolism and cardiovascular events, including myocardial infarction and cardiovascular death. However, the majority of studies that have analyzed the efficacy of anticoagulants have been focused only on their effects on the risk of stroke. Areas covered: The available evidence about the association between atrial fibrillation and cardiovascular disease as well as the effects of oral anticoagulation on cardiovascular death and myocardial infarction, with...
Source: Expert Opinion on Pharmacotherapy - December 8, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin
ConclusionsIn this example, different applications of the same PS led to substantially different results, a finding that was particularly apparent with IPTW, and this was remedied by truncating extreme weights. If IPTW is used, information regarding the weights applied along with sensitivity analyses could avoid misrepresentation of study results, and would enhance their interpretation.
Source: Drug Safety - November 28, 2016 Category: Drugs & Pharmacology Source Type: research

The Factor Xa Inhibitor Edoxaban for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation.
Authors: Minguet J, Sims HM, Smith KH, Bramlage P Abstract INTRODUCTION: With the rising prevalence of nonvalvular atrial fibrillation (NVAF) in the general population, the development of new drugs for prevention of thromboembolic events is essential. Non-vitamin K antagonist oral anticoagulants (NOACs) have been shown to present a number of advantages over conventionally used agents, such as predictable pharmacokinetics and no requirement for continuous anticoagulant monitoring. The most recently approved NOAC for the NVAF indication is edoxaban. Several subgroup analyses from the edoxaban phase III ENGAGE AF-TIMI...
Source: Expert Review of Clinical Pharmacology - November 9, 2016 Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research

Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation —a cohort study in primary care
ConclusionsIn this clinical setting, we found no evidence pointing to an increased risk of HS with antithrombotic treatment.
Source: European Journal of Clinical Pharmacology - November 7, 2016 Category: Drugs & Pharmacology Source Type: research